Recent Quotes (30 days)

You have no recent quotes
chg | %
WOOF90.90+0.0700.08%
ARIA23.70+0.0200.08%
.IXIC5,563.65+11.830.21%
.INX2,275.32+6.420.28%
.DJI19,954.28+98.750.50%
COMPOSITE5,301.24-8.69-0.16%
ME45,933.65+47.380.10%
IAR16,720.58-414.93-2.42%
TASI6,894.65-113.38-1.62%
WIG53,709.33+299.610.56%
IB9,408.60-43.40-0.46%
XU10077,666.58+272.890.35%
SET1,572.93+0.8300.05%
IBOV62,446.26+314.460.51%
ATX2,669.54+9.840.37%
SMI8,427.15-22.04-0.26%
TA251,458.71-1.33-0.09%
SENSEX27,140.41+240.850.90%
XJO5,786.00+14.500.30%
OSPTX15,491.54+65.260.42%

EXACT Sciences Corporation  

(Public, NASDAQ:EXAS)   Watch this stock  
Find more results for EXAS
18.66
+1.09 (6.20%)
After Hours: 18.66 0.00 (0.00%)
Jan 11, 6:31PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.13 - 18.77
52 week 4.67 - 22.80
Open 17.61
Vol / Avg. 6.06M/2.35M
Mkt cap 1.98B
P/E     -
Div/yield     -
EPS -1.72
Shares 108.41M
Beta 0.85
Inst. own 89%
Feb 22, 2017
Q4 2016 Exact Sciences Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 12, 2017
Exact Sciences Corp at JPMorgan Healthcare Conference - 10:30AM EST - Add to calendar
Nov 17, 2016
Exact Sciences Corp at Canaccord Genuity Med Tech Conference
Nov 16, 2016
Exact Sciences Corp at Craig-Hallum Alpha Select Conference
Nov 9, 2016
Exact Sciences Corp at Stephens Fall Investor Conference
Oct 26, 2016
Q3 2016 Exact Sciences Corp Earnings Call
Oct 26, 2016
Q3 2016 Exact Sciences Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -134.46% -400.14%
Operating margin -136.17% -403.35%
EBITD margin - -383.70%
Return on average assets -43.84% -46.63%
Return on average equity -49.57% -51.25%
Employees 677 -
CDP Score - -

Address

441 Charmany Dr
MADISON, WI 53719-1234
United States - Map
+1-608-2845700 (Phone)
+1-608-2845701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company's product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. It has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test. The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers. It also focused on developing its pipeline for future products and services.

Officers and directors

Kevin T. Conroy Chairman of the Board, President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Jeffrey T. Elliott Chief Financial Officer
Age: 39
Bio & Compensation  - Reuters
Maneesh K. Arora Chief Operating Officer, Senior Vice President, Director
Age: 47
Bio & Compensation  - Reuters
Graham Peter Lidgard Ph.D. Senior Vice President, Chief Scientific Officer
Age: 67
Bio & Compensation  - Reuters
D. Scott Coward Senior Vice President, General Counsel, Secretary
Age: 51
Bio & Compensation  - Reuters
David A. Thompson Lead Independent Director
Age: 74
Bio & Compensation  - Reuters
Thomas D. Carey Independent Director
Age: 54
Bio & Compensation  - Reuters
James E. Doyle Independent Director
Bio & Compensation  - Reuters
John A. Fallon M.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Daniel J. Levangie Independent Director
Age: 65
Bio & Compensation  - Reuters